Omnicell, Inc. (NASDAQ:OMCL) is Avory & Company LLC’s 9th Largest Position

Avory & Company LLC increased its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 25.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 193,162 shares of the company’s stock after acquiring an additional 39,386 shares during the period. Omnicell comprises approximately 5.1% of Avory & Company LLC’s portfolio, making the stock its 9th biggest holding. Avory & Company LLC’s holdings in Omnicell were worth $7,269,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. South Dakota Investment Council lifted its holdings in shares of Omnicell by 14.8% in the 4th quarter. South Dakota Investment Council now owns 21,727 shares of the company’s stock worth $818,000 after acquiring an additional 2,800 shares during the last quarter. California Public Employees Retirement System grew its stake in shares of Omnicell by 11.7% during the 4th quarter. California Public Employees Retirement System now owns 75,523 shares of the company’s stock worth $2,842,000 after purchasing an additional 7,902 shares during the period. Strs Ohio increased its holdings in Omnicell by 28.2% in the 4th quarter. Strs Ohio now owns 5,000 shares of the company’s stock worth $188,000 after acquiring an additional 1,100 shares in the last quarter. Louisiana State Employees Retirement System acquired a new stake in Omnicell in the 4th quarter valued at about $854,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Omnicell by 3.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 638,646 shares of the company’s stock worth $24,032,000 after acquiring an additional 19,601 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on OMCL. Barclays started coverage on shares of Omnicell in a research note on Wednesday, January 3rd. They set an “underweight” rating and a $33.00 target price on the stock. Wells Fargo & Company lowered their target price on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating for the company in a report on Friday, February 9th. Finally, Benchmark reissued a “buy” rating and issued a $38.00 price objective on shares of Omnicell in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $42.20.

Omnicell Stock Performance

Shares of OMCL stock traded down $0.18 during trading hours on Tuesday, reaching $27.22. The stock had a trading volume of 151,318 shares, compared to its average volume of 532,490. The firm has a 50-day simple moving average of $27.64 and a 200-day simple moving average of $32.04. The firm has a market capitalization of $1.25 billion, a PE ratio of -60.07 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.52 and a quick ratio of 2.22. Omnicell, Inc. has a twelve month low of $25.69 and a twelve month high of $77.14.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. The company had revenue of $258.85 million for the quarter, compared to analyst estimates of $256.00 million. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. As a group, equities analysts forecast that Omnicell, Inc. will post 0.09 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.